Compounds > metformin
Page last updated: 2024-10-30

metformin and Kidney Diseases

metformin has been researched along with Kidney Diseases in 74 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.

Research Excerpts

ExcerptRelevanceReference
"Lactic acidosis in diabetic patients undergoing metformin therapy is a widely recognized, rare but usually serious adverse event, particularly in presence of comorbidities such as cardiorespiratory disease, sepsis and renal failure."8.88Iodine-based radiographic contrast medium may precipitate metformin-associated lactic acidosis in diabetic patients. A case report, literature review and practical approach. ( Tonolini, M, 2012)
" In this study, we investigated its effects on renal fibrosis in a mouse model of unilateral ureteral obstruction (UUO) in vivo and in angiotensin II (Ang II)-treated renal fibroblast NRK-49F cells in vitro."7.83Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts. ( Gan, X; Lu, L; Miao, N; Shen, Y; Xu, D; Xu, J; Xue, H; Zhang, W; Zhou, L, 2016)
"Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes mellitus (T2DM), acting via indirect activation of 5' Adenosine monophosphate-activated Protein Kinase (AMPK)."6.72Mechanism and application of metformin in kidney diseases: An update. ( Meng, X; Song, A; Zhang, C, 2021)
"Metformin is a widely used antidiabetic agent that is generally considered safe."5.37Metformin-associated lactic acidosis in Chinese patients with type II diabetes. ( Chan, WM; Chung, HY; Fong, BM; Siu, TS; Tam, S; Tsai, NW; Tsui, SH; Yeung, CW, 2011)
"Lactic acidosis is a rare side effect of metformin."5.34[Metformin-related lactic acidosis in an 85-year-old woman]. ( Jansen, PA; Knol, W; van der Linden, CM; van Marum, RJ, 2007)
" The primary outcomes were mortality, occurrence of lactic acidosis and myocardial infarction (MI) in patients taking metformin during dialysis treatment for ≥12 months (long term)."5.01Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. ( Abdel Shaheed, C; Carland, JE; Chowdhury, G; Day, RO; Furlong, T; Graham, GG; Greenfield, JR; Hicks, M; Macdonald, P; Smith, FC; Smith, G; Stocker, SL; Williams, KM, 2019)
"A literature search was performed in PUBMED, ScienceDirect, between January 1957 and March 2017 using the following keywords: "metformin," "nephroprotection," "renoprotection," "survival," "renal failure," "chronic kidney diseases," "fibrosis," "polycystic kidney disease" and "microalbuminuria."4.98Renoprotective Effects of Metformin. ( De Broe, ME; Kajbaf, F; Lalau, JD, 2018)
" She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine."4.98Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. ( Anderson, K; Facon, T, 2018)
" She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine."4.98Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. ( Anderson, KC; Wildes, TM, 2018)
" We will discuss a range of adverse events to iodinated and gadolinium-based contrast agents, including allergic-like reactions, nephrotoxicity, extravasation, and nephrogenic systemic fibrosis."4.91Intravenous Imaging Contrast Media Complications: The Basics That Every Clinician Needs to Know. ( Choi, JW; Rose, TA, 2015)
"The search included comparative trials, observational cohort studies, and meta-analyses using the terms diabetes mellitus, metformin, renal insufficiency, and acidosis, lactic."4.89Unleash metformin: reconsideration of the contraindication in patients with renal impairment. ( Braun, A; Defilippi, J; Lu, WR, 2013)
"Lactic acidosis in diabetic patients undergoing metformin therapy is a widely recognized, rare but usually serious adverse event, particularly in presence of comorbidities such as cardiorespiratory disease, sepsis and renal failure."4.88Iodine-based radiographic contrast medium may precipitate metformin-associated lactic acidosis in diabetic patients. A case report, literature review and practical approach. ( Tonolini, M, 2012)
" The use of ICM in diabetic patients receiving metformin should be carried out with care to avoid metformin-induced lactic acidosis."4.81Adverse reactions to iodinated contrast media. ( Morcos, SK; Thomsen, HS, 2001)
"Twenty female pregnant rats were used, and they were divided into four groups of control (normal pregnancy), disease (diabetic untreated), metformin (received 200 mg/kg metformin dissolved in distilled water) and tBHQ groups (received 25 mg/kg tBHQ in 1% corn oil), respectively, with five rats in each group."4.31Tert-butylhydroquinone Mitigates Renal Dysfunction in Pregnant Diabetic Rats ( Li, J; Liu, H; Shang, L, 2023)
" The moderate hyperglycaemia seen in prediabetes can be treated using a combination of metformin and lifestyle interventions (low-calorie diets and exercising)."4.12Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats. ( Akinnuga, AM; Booysen, IN; Ismail, MB; Khathi, A; Khumalo, B; Ngubane, P; Sibiya, NH; Siboto, A, 2022)
"These data indicate the presence of a coexisting risk factor, other than metformin use, associated with metabolic acidosis after contrast medium exposure."3.83The association between use of metformin and change in serum CO2 level after administration of contrast medium. ( Baek, JH; Hahm, JR; Jung, J; Jung, JH; Kim, KY; Kim, SK, 2016)
" In this study, we investigated its effects on renal fibrosis in a mouse model of unilateral ureteral obstruction (UUO) in vivo and in angiotensin II (Ang II)-treated renal fibroblast NRK-49F cells in vitro."3.83Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts. ( Gan, X; Lu, L; Miao, N; Shen, Y; Xu, D; Xu, J; Xue, H; Zhang, W; Zhou, L, 2016)
"Current studies point to a weak causal relationship between metformin and lactic acidosis."3.75Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? ( Ernst, ME; McDanel, DL; Moores, KG; Philbrick, AM; Ross, MB, 2009)
"Mean composite kidney disease progression occurred in 135 (10."3.30Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. ( Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N, 2023)
"Alprostadil hydration was superior to drinking water monohydration regarding preventing CIN in T2DM patients treated with metformin after contrast-enhanced CT."2.84Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. ( Ai, X; Gao, Y; Li, C; Li, L; Sun, N; Sun, W; Wang, J, 2017)
" Both sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) showed moderate to high certainty in reducing risk of 3-point major adverse cardiovascular events, 3P-MACE (network estimates: SGLT2i [RR 0."2.82Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. ( Chong, CW; Fong, AYY; Hussein, Z; Khunti, K; Lee, SWH; Loganadan, NK; Navaravong, L; Sim, R, 2022)
"Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes mellitus (T2DM), acting via indirect activation of 5' Adenosine monophosphate-activated Protein Kinase (AMPK)."2.72Mechanism and application of metformin in kidney diseases: An update. ( Meng, X; Song, A; Zhang, C, 2021)
"Metformin is an established insulin receptor sensitising antihyperglycemic agent, is highly affordable, and has superior safety and efficacy profiles."2.72Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. ( Driver, C; Gcwensa, SK; Mbara, KC; Mcobothi, EN; Mkhombo, NT; Mofo Mato, PE; Nzuza, S; Owira, PM, 2021)
"Metformin is a kind of biguanide hypoglycemic agent that has been widely used in patients with diabetes mellitus."2.55Can Fundus Fluorescein Angiography be Performed for Diabetic Patients on Oral Metformin?. ( Du, J; Li, R, 2017)
"Metformin was administered via drinking water to mice with a unilateral ureteric obstruction (UUO) model of renal fibrosis."1.91Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney. ( Gleich, K; Harley, G; Katerelos, M; Lee, M; Mount, PF; Power, DA, 2023)
"Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE)."1.62Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study. ( Alexander, GC; Baksh, S; Chang, HY; Ehrhardt, S; Mansour, O; McAdams-DeMarco, M; Segal, JB; Wen, J, 2021)
"We aimed to develop a metformin dosing strategy to optimise efficacy and safety in patients with reduced kidney function."1.62Metformin doses to ensure efficacy and safety in patients with reduced kidney function. ( Cosgrove, S; Kuan, IHS; Leishman, JC; Putt, TL; Schollum, JBW; Walker, RJ; Wilson, LC; Wright, DFB, 2021)
"Metformin, the first-line drug to treat type 2 diabetes (T2D), inhibits mitochondrial glycerolphosphate dehydrogenase in the liver to suppress gluconeogenesis."1.51Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. ( Berg, M; Dash, SN; Dumont, V; Groop, PH; Hautala, LC; Lehtonen, S; Lindfors, S; Mirtti, T; Naams, JB; Nisen, H; Polianskyte-Prause, Z; Tienari, J; Tolvanen, TA; Van, M; Wähälä, K; Wang, H, 2019)
"Dapagliflozin or metformin treatment decreased insulin resistance, hypercholesterolemia, creatinine clearance and renal oxidative stress leading to improved renal function."1.48Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model. ( Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, L; Wanchai, K, 2018)
"Metformin has a well described antifibrotic effect, and increases phosphorylation of ACC by AMPK, thereby increasing FAO."1.48Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin. ( Galic, S; Gleich, K; Katerelos, M; Kemp, BE; Lee, M; Mount, PF; Power, DA, 2018)
"The PBPK model reasonably predicted the pharmacokinetic profiles of metformin for both young adults and the elderly."1.46Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations. ( Chung, H; Chung, JY; Rhee, SJ; Yi, S; Yu, KS, 2017)
"The Cardiff Model was used to simulate disease progression and estimate the long-term effect of treatments on patients."1.42Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. ( Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L, 2015)
"Metformin is a widely used antidiabetic agent that is generally considered safe."1.37Metformin-associated lactic acidosis in Chinese patients with type II diabetes. ( Chan, WM; Chung, HY; Fong, BM; Siu, TS; Tam, S; Tsai, NW; Tsui, SH; Yeung, CW, 2011)
"Metformin treatment fully blocked gentamicin-mediated acute renal failure."1.36Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. ( Arévalo, M; Briones, E; Detaille, D; El-Mir, MY; Leverve, X; López-Novoa, JM; Morales, AI; Prieto, M; Puente, A, 2010)
"Of 19,981 patients with Type 2 diabetes, 11,297 were taking metformin in accordance with our current guideline."1.34Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. ( McKnight, JA; Strachan, MW; Warren, RE; Wild, S, 2007)
"Lactic acidosis is a rare side effect of metformin."1.34[Metformin-related lactic acidosis in an 85-year-old woman]. ( Jansen, PA; Knol, W; van der Linden, CM; van Marum, RJ, 2007)
"The development of acute renal failure significantly complicates intravascular contrast medium (CM) use and is linked with high morbidity and mortality."1.34Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. ( Barrett, B; Benko, A; Capusten, B; Fraser-Hill, M; Magner, P; Myers, A; Owen, RJ, 2007)
"6%, possibly not as a consequence of low bioavailability (a similar low recovery was found after oral administration of the metformin solution used for the intravenous studies), but of binding to the intestinal wall, as shown in animal and clinical studies with metformin and other biguanides."1.26Disposition of metformin (N,N-dimethylbiguanide) in man. ( Bondioli, A; Cighetti, G; Conti, F; Franceschini, G; Galli, G; Galli-Kienle, M; Sirtori, CR, 1978)

Research

Studies (74)

TimeframeStudies, this research(%)All Research%
pre-19903 (4.05)18.7374
1990's2 (2.70)18.2507
2000's16 (21.62)29.6817
2010's38 (51.35)24.3611
2020's15 (20.27)2.80

Authors

AuthorsStudies
Seikrit, C1
Lausberg, E1
Buhl, EM1
Gaspar, R1
Tabi, T1
Heffer, M1
Ducza, E1
Sztojkov-Ivanov, A1
Seres, AB1
Szucs, K1
Ivic, V1
Floege, J1
Vari, SG1
Boor, P1
Klinkhammer, BM1
Sim, R1
Chong, CW1
Loganadan, NK1
Fong, AYY1
Navaravong, L1
Hussein, Z1
Khunti, K1
Lee, SWH1
Li, J8
Liu, H2
Shang, L1
Gerard, E1
Quindroit, P1
Lemaitre, M1
Robert, L1
Gautier, S1
Decaudin, B1
Vambergue, A1
Beuscart, JB1
Siboto, A2
Akinnuga, AM2
Khumalo, B2
Ismail, MB2
Booysen, IN2
Sibiya, NH2
Ngubane, P2
Khathi, A2
Harley, G1
Katerelos, M2
Gleich, K2
Lee, M2
Mount, PF2
Power, DA2
Thongnak, L2
Pengrattanachot, N1
Promsan, S1
Phengpol, N1
Sutthasupha, P1
Jaikumkao, K2
Lungkaphin, A2
Wexler, DJ1
de Boer, IH1
Ghosh, A1
Younes, N1
Bebu, I1
Inzucchi, SE1
McGill, JB2
Mudaliar, S1
Schade, D1
Steffes, MW1
Tamborlane, WV1
Tan, MH1
Ismail-Beigi, F1
Molitch, ME1
Tripputi, M1
Levey, AS1
Crandall, JP1
Dabelea, D1
Herman, WH1
Knowler, WC1
Orchard, TJ1
Schroeder, EB1
Srikanthan, P1
Temprosa, M1
White, NH1
Nathan, DM1
Abdel Shaheed, C1
Carland, JE1
Graham, GG1
Stocker, SL1
Smith, G1
Hicks, M1
Williams, KM1
Furlong, T1
Macdonald, P1
Greenfield, JR1
Smith, FC1
Chowdhury, G1
Day, RO1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L3
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J5
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y3
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H2
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H3
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C2
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q2
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S2
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC2
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H2
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Vangaveti, S1
Das, P1
Kumar, VL1
Kuan, IHS1
Wilson, LC1
Leishman, JC1
Cosgrove, S1
Walker, RJ1
Putt, TL1
Schollum, JBW1
Wright, DFB1
Mbara, KC1
Mofo Mato, PE1
Driver, C1
Nzuza, S1
Mkhombo, NT1
Gcwensa, SK1
Mcobothi, EN1
Owira, PM1
Song, A1
Zhang, C1
Meng, X1
Baksh, S1
Wen, J1
Mansour, O1
Chang, HY1
McAdams-DeMarco, M1
Segal, JB1
Ehrhardt, S1
Alexander, GC1
Rhee, SJ1
Chung, H1
Yi, S1
Yu, KS1
Chung, JY1
Ai, X1
Li, L1
Sun, N1
Sun, W1
Du, J1
Li, R1
De Broe, ME1
Kajbaf, F1
Lalau, JD1
Eder, S1
Leierer, J1
Kerschbaum, J1
Rosivall, L1
Wiecek, A1
de Zeeuw, D1
Mark, PB1
Heinze, G1
Rossing, P1
Heerspink, HL1
Mayer, G1
Pongchaidecha, A1
Chueakula, N1
Wanchai, K1
Chatsudthipong, V1
Chattipakorn, N1
Galic, S1
Kemp, BE1
Guo, D1
Bae, HJ1
Obianom, O1
Zeng, S1
Su, T1
Polli, JE1
Shu, Y1
Polianskyte-Prause, Z1
Tolvanen, TA1
Lindfors, S1
Dumont, V1
Van, M1
Dash, SN1
Berg, M1
Naams, JB1
Hautala, LC1
Nisen, H1
Mirtti, T1
Groop, PH1
Wähälä, K1
Tienari, J1
Lehtonen, S1
Wang, SY1
Cai, GY1
Chen, XM1
Facon, T1
Anderson, K1
Wildes, TM1
Bergmark, BA1
Bhatt, DL1
McGuire, DK1
Cahn, A1
Mosenzon, O1
Steg, PG1
Im, K1
Kanevsky, E1
Gurmu, Y1
Raz, I1
Braunwald, E1
Scirica, BM1
Li, YC4
Shih, YM2
Lee, JA4
Gómez Herrero, H1
De Arriba Villamor, C1
Buldain Parra, M1
Arraiza Sarasa, M1
Lu, WR1
Defilippi, J1
Braun, A1
Huang, TC1
Chen, SM3
Moon, SY1
Kim, JS1
Baek, CH1
Kim, M1
Min, JY1
Lee, SK1
Rose, TA1
Choi, JW1
Chowdhury, TA1
Wright, R1
Yaqoob, MM1
Deng, J1
Shi, L1
Mu, Y1
Dong, H1
Chou, CK1
Shen, Y1
Miao, N1
Xu, J1
Gan, X1
Xu, D1
Xue, H1
Zhang, W1
Lu, L1
Weinrauch, LA1
D'Elia, JA1
Finn, P1
Lewis, EF1
Desai, AS1
Claggett, BL1
Cooper, ME1
Kim, SK1
Jung, J1
Jung, JH1
Kim, KY1
Baek, JH1
Hahm, JR1
Gai, Z1
Visentin, M1
Hiller, C1
Krajnc, E1
Li, T1
Zhen, J1
Kullak-Ublick, GA1
Aschenbrenner, DS1
Huang, YS1
Tsai, PY1
Lin, CE1
Chen, CM1
Kuefner, MA1
Heinrich, M1
Bautz, W1
Uder, M1
Philbrick, AM1
Ernst, ME1
McDanel, DL1
Ross, MB1
Moores, KG1
Morales, AI1
Detaille, D1
Prieto, M1
Puente, A1
Briones, E1
Arévalo, M1
Leverve, X1
López-Novoa, JM1
El-Mir, MY1
Zorov, DB1
Pilmore, HL1
Vasisht, KP1
Chen, SC1
Peng, Y1
Bakris, GL1
Yeung, CW1
Chung, HY1
Fong, BM1
Tsai, NW1
Chan, WM1
Siu, TS1
Tam, S1
Tsui, SH1
Cosmi, F1
Cosmi, D1
Benetti, A1
Garbossa, SG1
Veronelli, A1
Pontiroli, AE1
Tonolini, M1
Høieggen, A1
Os, I1
Thomsen, HS2
Morcos, SK2
Chong, W1
Gross, JL1
Friedman, R1
Silveiro, SP1
Namasivayam, S1
Kalra, MK1
Torres, WE1
Small, WC1
Warren, RE1
Strachan, MW1
Wild, S1
McKnight, JA1
van der Linden, CM1
Knol, W1
van Marum, RJ1
Jansen, PA1
Benko, A1
Fraser-Hill, M1
Magner, P1
Capusten, B1
Barrett, B1
Myers, A1
Owen, RJ1
Offerhaus, L1
Wensveen, BM1
Wijbenga, JA1
Berend, K1
Kühnau, J1
Nolan, DB1
Quasny, H1
Clouâtre, Y1
Bakris, G1
Funaki, B1
Sirtori, CR1
Franceschini, G1
Galli-Kienle, M1
Cighetti, G1
Galli, G1
Bondioli, A1
Conti, F1
Schneider, T1
Lopis, S1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes[NCT01107886]Phase 418,206 participants (Actual)Interventional2010-05-31Completed
Prospective, Double Blind, Randomized Trial: Meniscal Repair With or Without Augmentation Utilizing Platelet Rich Plasma.[NCT01991353]0 participants (Actual)Interventional2015-07-31Withdrawn (stopped due to Lack of funding)
The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate[NCT01210456]Phase 3458 participants (Anticipated)Interventional2009-10-31Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke

Participants with CV death, non-fatal MI or non-fatal ischaemic stroke. If no event, censoring occurs at the patient withdrawal of consent, last contact, or death (when applicable)-whichever was later. (NCT01107886)
Timeframe: Randomization (day 0) up to 2.9 years

Interventionparticipants (Number)
Saxagliptin613
Placebo609

Participants With Any Event From the Composite of CV Death, Non-fatal MI, Non-fatal Ischaemic Stroke, Hospitalisation for Heart Failure, Hospitalisation for Unstable Angina Pectoris, or Hospitalisation for Coronary Revascularisation

Participants with CV death, non-fatal MI, non-fatal ischaemic stroke, hospitalisation for heart failure, hospitalisation for unstable angina pectoris, or hospitalisation for coronary revascularisation. If no event, censoring occurs at the patient withdrawal of consent, last contact, or death (when applicable)-whichever was later. (NCT01107886)
Timeframe: Randomization (day 0) up to 2.9 years

Interventionparticipants (Number)
Saxagliptin1059
Placebo1034

Participants With Event of Death

Participants with event of death. If no event, censoring occurs at the patient withdrawal of consent, or last contact -whichever was later. (NCT01107886)
Timeframe: Randomization (day 0) up to 2.9 years

Interventionparticipants (Number)
Saxagliptin420
Placebo378

Reviews

21 reviews available for metformin and Kidney Diseases

ArticleYear
Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Diabetic medicine : a journal of the British Diabetic Association, 2022, Volume: 39, Issue:3

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypogl

2022
Defining explicit definitions of potentially inappropriate prescriptions for antidiabetic drugs in patients with type 2 diabetes: A systematic review.
    PloS one, 2022, Volume: 17, Issue:9

    Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inappropriate Prescribing; Kidney Dise

2022
Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:12

    Topics: Acidosis; Diabetes Mellitus, Type 2; Drug Monitoring; Humans; Hypoglycemic Agents; Kidney; Kidney Di

2019
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications.
    European journal of pharmacology, 2021, May-05, Volume: 898

    Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cardiovascular Diseases; COVID-19; COVID-19 D

2021
Mechanism and application of metformin in kidney diseases: An update.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 138

    Topics: Acidosis, Lactic; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Diabetic Nephro

2021
Can Fundus Fluorescein Angiography be Performed for Diabetic Patients on Oral Metformin?.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2017, Jun-10, Volume: 32, Issue:2

    Topics: Administration, Oral; Contrast Media; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fluorescein A

2017
Renoprotective Effects of Metformin.
    Nephron, 2018, Volume: 138, Issue:4

    Topics: Animals; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin; Protective Agents

2018
Energy restriction in renal protection.
    The British journal of nutrition, 2018, Volume: 120, Issue:10

    Topics: Aging; Animals; Autophagy; Caloric Restriction; Diet; Energy Metabolism; Female; Humans; Inflammatio

2018
Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist.
    Hematology. American Society of Hematology. Education Program, 2018, 11-30, Volume: 2018, Issue:1

    Topics: Aged; Diabetes Mellitus; Female; Fractures, Compression; Humans; Hypertension; Kidney Diseases; Metf

2018
Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.
    Hematology. American Society of Hematology. Education Program, 2018, 11-30, Volume: 2018, Issue:1

    Topics: Aged; Diabetes Mellitus; Female; Fractures, Compression; Health Services for the Aged; Humans; Hyper

2018
Unleash metformin: reconsideration of the contraindication in patients with renal impairment.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:11

    Topics: Acidosis, Lactic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney

2013
Intravenous Imaging Contrast Media Complications: The Basics That Every Clinician Needs to Know.
    The American journal of medicine, 2015, Volume: 128, Issue:9

    Topics: Contrast Media; Extravasation of Diagnostic and Therapeutic Materials; Fibrosis; Gadolinium; Humans;

2015
[Suggestions for prevention of adverse reactions after intravasal administration of iodinated contrast media].
    Rontgenpraxis; Zeitschrift fur radiologische Technik, 2008, Volume: 56, Issue:6

    Topics: Adrenal Cortex Hormones; Anaphylaxis; Animals; Contrast Media; Creatinine; Glomerular Filtration Rat

2008
Amelioration of aminoglycoside nephrotoxicity requires protection of renal mitochondria.
    Kidney international, 2010, Volume: 77, Issue:10

    Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Cell Death; Gentamicins; Hypoglycemic Agents; Kidne

2010
Review: metformin: potential benefits and use in chronic kidney disease.
    Nephrology (Carlton, Vic.), 2010, Volume: 15, Issue:4

    Topics: Acidosis, Lactic; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Nephropathies;

2010
[Metformin and insulin in chronic heart failure: contraindications not contraindicated and indications not indicated].
    Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:12

    Topics: Acidosis, Lactic; Cardiovascular Agents; Clinical Trials as Topic; Contraindications; Diabetes Melli

2011
Iodine-based radiographic contrast medium may precipitate metformin-associated lactic acidosis in diabetic patients. A case report, literature review and practical approach.
    La Clinica terapeutica, 2012, Volume: 163, Issue:1

    Topics: Acidosis, Lactic; Aged, 80 and over; Atrial Fibrillation; Contraindications; Contrast Media; Creatin

2012
Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines.
    The British journal of radiology, 2003, Volume: 76, Issue:908

    Topics: Biomarkers; Contraindications; Contrast Media; Creatinine; Glomerular Filtration Rate; Humans; Hypog

2003
Adverse reactions to intravenous iodinated contrast media: a primer for radiologists.
    Emergency radiology, 2006, Volume: 12, Issue:5

    Topics: Acidosis, Lactic; Contrast Media; Drug Hypersensitivity; Humans; Incidence; Injections, Intravenous;

2006
Adverse reactions to iodinated contrast media.
    European radiology, 2001, Volume: 11, Issue:7

    Topics: Acidosis, Lactic; Contrast Media; Drug Hypersensitivity; Humans; Hypoglycemic Agents; Injections; Io

2001

Trials

6 trials available for metformin and Kidney Diseases

ArticleYear
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    JAMA internal medicine, 2023, 07-01, Volume: 183, Issue:7

    Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Ra

2023
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy.
    International urology and nephrology, 2017, Volume: 49, Issue:11

    Topics: Aged; Alprostadil; Contrast Media; Creatinine; Diabetes Mellitus, Type 2; Emergencies; Female; Fluid

2017
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial.
    Circulation, 2019, 09-17, Volume: 140, Issue:12

    Topics: Aged; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failur

2019
Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Diabetes research and clinical practice, 2016, Volume: 113

    Topics: Aged; Anemia; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypoglyce

2016
HB419 (glibenclamide) in the treatment of diabetes mellitus.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1969, Aug-09, Volume: 43, Issue:32

    Topics: Adult; Age Factors; Aged; Biguanides; Chlorpropamide; Clinical Trials as Topic; Diabetes Complicatio

1969

Other Studies

48 other studies available for metformin and Kidney Diseases

ArticleYear
A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2021, Dec-23, Volume: 55, Issue:S4

    Topics: Animals; Diet, High-Fat; Female; Kidney Diseases; Liraglutide; Male; Metabolic Syndrome; Metformin;

2021
Tert-butylhydroquinone Mitigates Renal Dysfunction in Pregnant Diabetic Rats
    Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:5

    Topics: Animals; Antioxidants; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes, Gestat

2023
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney

2022
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney

2022
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney

2022
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney

2022
Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney.
    PloS one, 2023, Volume: 18, Issue:2

    Topics: Animals; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Metformin; Mice; Mutation; Phosp

2023
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.
    Archives of pharmacal research, 2023, Volume: 46, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Ki

2023
Effects of metformin and intensive lifestyle interventions on the incidence of kidney disease in adults in the DPP/DPPOS.
    Journal of diabetes and its complications, 2023, Volume: 37, Issue:9

    Topics: Adult; Diabetes Mellitus, Type 2; Humans; Incidence; Kidney Diseases; Life Style; Metformin

2023
Metformin and silymarin afford protection in cyclosporine A induced hepatorenal toxicity in rat by modulating redox status and inflammation.
    Journal of biochemical and molecular toxicology, 2021, Volume: 35, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cyclosporine; Inflammation; Kidney Diseases; Male;

2021
Metformin doses to ensure efficacy and safety in patients with reduced kidney function.
    PloS one, 2021, Volume: 16, Issue:2

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Dosage Calculations; Female; Humans; Hypoglycemic Agent

2021
Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
    Scientific reports, 2021, 08-17, Volume: 11, Issue:1

    Topics: Adult; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV I

2021
Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
    European journal of drug metabolism and pharmacokinetics, 2017, Volume: 42, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Computer Simulation; Female; Humans; Kidney Diseases; L

2017
A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics.
    Kidney & blood pressure research, 2018, Volume: 43, Issue:1

    Topics: Aged; Biomarkers; Cardiovascular Diseases; Clinical Protocols; Cohort Studies; Diabetes Mellitus, Ty

2018
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Biochimica et biophysica acta. Molecular basis of disease, 2018, Volume: 1864, Issue:6 Pt A

    Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Insulin;

2018
Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin.
    Journal of the American Society of Nephrology : JASN, 2018, Volume: 29, Issue:9

    Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Analysis of Variance; Animals; Biopsy, Needle

2018
Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
    Pharmaceutical research, 2018, Sep-06, Volume: 35, Issue:11

    Topics: Animals; Antineoplastic Agents; Carvedilol; Cell Survival; Cisplatin; HEK293 Cells; Humans; Kidney;

2018
Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:2

    Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expressio

2019
Gentamicin caused renal injury deeply related to methylglyoxal and N(ɛ)-(carboxyethyl)lysine (CEL).
    Toxicology letters, 2013, May-10, Volume: 219, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Antioxidants; Gentamicins; Glutathione; Immunohistochemistry; Kidney

2013
[Nephrotoxicity due to iodine contrasts in computerized tomography studies of diabetic outpatients on metformin].
    Anales del sistema sanitario de Navarra, 2013, Sep-06, Volume: 36, Issue:2

    Topics: Aged; Contrast Media; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Incidence; Iodine Comp

2013
Increased renal semicarbazide-sensitive amine oxidase activity and methylglyoxal levels in aristolochic acid-induced nephrotoxicity.
    Life sciences, 2014, Sep-26, Volume: 114, Issue:1

    Topics: Amine Oxidase (Copper-Containing); Animals; Aristolochic Acids; Dose-Response Relationship, Drug; Ki

2014
Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis.
    American journal of physiology. Renal physiology, 2015, Feb-01, Volume: 308, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP;

2015
Using metformin in the presence of renal disease.
    BMJ (Clinical research ed.), 2015, Apr-14, Volume: 350

    Topics: Acidosis, Lactic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney

2015
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Journal of medical economics, 2015, Volume: 18, Issue:10

    Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analy

2015
Chitosan Prevents Gentamicin-Induced Nephrotoxicity via a Carbonyl Stress-Dependent Pathway.
    BioMed research international, 2015, Volume: 2015

    Topics: Animals; Blood Urea Nitrogen; Chitosan; Gentamicins; Humans; Kidney; Kidney Diseases; Metabolic Netw

2015
Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts.
    International journal of molecular sciences, 2016, Jan-22, Volume: 17, Issue:2

    Topics: Angiotensin II; Animals; Disease Models, Animal; Extracellular Matrix Proteins; Fibroblasts; Gene Ex

2016
The association between use of metformin and change in serum CO2 level after administration of contrast medium.
    Clinical radiology, 2016, Volume: 71, Issue:6

    Topics: Acidosis; Administration, Oral; Aged; Carbon Dioxide; Comorbidity; Contrast Media; Creatinine; Dose-

2016
Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9

    Topics: Animals; Cell Line; Diet, High-Fat; Female; Gentamicins; HEK293 Cells; Humans; Kidney; Kidney Diseas

2016
The FDA Revises Restrictions on Metformin Use in Kidney Impairment.
    The American journal of nursing, 2016, Volume: 116, Issue:8

    Topics: Contraindications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glomerular Filtration Rate; H

2016
Accumulation of methylglyoxal and d-lactate in Pb-induced nephrotoxicity in rats.
    Biomedical chromatography : BMC, 2017, Volume: 31, Issue:5

    Topics: Animals; Biomarkers; Body Weight; Creatinine; Kidney; Kidney Diseases; L-Lactate Dehydrogenase; Lact

2017
Metformin use in renal dysfunction: is a serum creatinine threshold appropriate?
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Nov-15, Volume: 66, Issue:22

    Topics: Acidosis, Lactic; Creatinine; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney Disease

2009
Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.
    Kidney international, 2010, Volume: 77, Issue:10

    Topics: Acetylglucosaminidase; Animals; Antioxidants; Apoptosis; Cytochrome c Group; Cytochromes c; Electron

2010
Limitations of metformin use in patients with kidney disease: are they warranted?
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:12

    Topics: Acidosis, Lactic; Adolescent; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathi

2010
Metformin-associated lactic acidosis in Chinese patients with type II diabetes.
    Pharmacology, 2011, Volume: 88, Issue:5-6

    Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Amylases; Asian People; China; Creatinine; Diabete

2011
Acute renal failure after intragastric balloon in morbidly-obese metformin-treated diabetic patients. Report of two cases.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2012, Volume: 22, Issue:2

    Topics: Adult; Diabetes Mellitus; Female; Gastric Balloon; Humans; Kidney Diseases; Male; Metformin; Middle

2012
[Kidney injuries caused by drugs].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012, Jun-26, Volume: 132, Issue:12-13

    Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Contraindications

2012
Metformin and serious adverse effects.
    The Medical journal of Australia, 2004, Jul-05, Volume: 181, Issue:1

    Topics: Contrast Media; Drug Interactions; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin; Practice

2004
Preventing nephropathy induced by contrast medium.
    The New England journal of medicine, 2006, Apr-27, Volume: 354, Issue:17

    Topics: Contraindications; Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; K

2006
Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin.
    Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:5

    Topics: Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Fil

2007
[Metformin-related lactic acidosis in an 85-year-old woman].
    Nederlands tijdschrift voor geneeskunde, 2007, Apr-28, Volume: 151, Issue:17

    Topics: Acidosis, Lactic; Aged, 80 and over; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Fatal

2007
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
[Metformin-related lactic acidosis in an 85-year-old woman].
    Nederlands tijdschrift voor geneeskunde, 2007, Jul-28, Volume: 151, Issue:30

    Topics: Aged, 80 and over; Contraindications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents

2007
[Metformin-related lactic acidosis in an 85-year-old woman].
    Nederlands tijdschrift voor geneeskunde, 2007, Jul-28, Volume: 151, Issue:30

    Topics: Aged, 80 and over; Contraindications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents

2007
[Metformin-related lactic acidosis in an 85-year-old woman].
    Nederlands tijdschrift voor geneeskunde, 2007, Jul-28, Volume: 151, Issue:30

    Topics: Aged, 80 and over; Contraindications; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; F

2007
[Metformin in combination therapy of diabetes mellitus. Advantages and reservations].
    Deutsche medizinische Wochenschrift (1946), 1983, Jul-15, Volume: 108, Issue:28-29

    Topics: Acidosis; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Drug Therapy, Combination; Huma

1983
Theophylline option for attenuating contrast media-induced nephrotoxicity in patients on metformin.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Mar-01, Volume: 54, Issue:5

    Topics: Acidosis, Lactic; Contraindications; Contrast Media; Diabetes Mellitus, Type 2; Humans; Hypoglycemic

1997
Metformin, contrast media, and theophylline.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Sep-01, Volume: 54, Issue:17

    Topics: Acidosis, Lactic; Contraindications; Contrast Media; Diabetes Mellitus, Type 2; Humans; Hypoglycemic

1997
Lowering C-peptide levels and renoprotective therapy.
    Kidney international, 2000, Volume: 57, Issue:6

    Topics: C-Peptide; Contraindications; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin

2000
Oral antidiabetic agents safe with renal disease?
    Postgraduate medicine, 2000, Volume: 107, Issue:7

    Topics: Aged; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic

2000
Re: Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention.
    Journal of vascular and interventional radiology : JVIR, 2001, Volume: 12, Issue:7

    Topics: Acetylcysteine; Contrast Media; Humans; Kidney Diseases; Metformin

2001
Disposition of metformin (N,N-dimethylbiguanide) in man.
    Clinical pharmacology and therapeutics, 1978, Volume: 24, Issue:6

    Topics: Administration, Oral; Adult; Aged; Blood Proteins; Dose-Response Relationship, Drug; Female; Humans;

1978